Table 1.

General characteristics of our study population

Agea	10 (SD 4,7)
Male/female	23/28
Total	51
Type OI
I	24
III	13
IV	12
Unknown	2
Bisphosphonates
Risedronateb	34
Pamidronatec	15
Alendronated	2

^aMean in years

^bAdministered 1dd 5 mg orally

^cAdministered intravenously at a dose of 2 mg/kg given every 3 months

^dAdministered 70 mg orally once a week